Kevin Krenitsk

Biography

"With more than 15 years of experience leading and managing global diagnostic and biotechnology operations, including senior commercial and operational responsibilities at Foundation Medicine, Dr. Krenitsky recently joined OpGen as President to oversee the rollout of the company’s Acuitas® MDRO (Multi-Drug Resistant Organisms) family of Gene Tests and the Acuitas Lighthouse™ MDRO Management System, which is in development. Through December 2014, Dr. Krenitsky was chief commercial officer & SVP of International Strategy and previously chief operating officer of Foundation Medicine. He joined Foundation in June 2011 and was instrumental in taking the company from a start-up organization to a successful IPO in 2013, followed by a major $1.2B investment by Roche making them majority stakeholders. Prior to Foundation Medicine, he served as president of Enzo Clinical Labs, where he instituted a comprehensive strategic and operational plan that led to the introduction and launch of numerous FDA-approved esoteric tests, as well as several new laboratory developed tests. Dr. Krenitsky served as chief executive officer at both BioServe Biotechnologies, a global biotechnology company specializing in processing genetic diagnostic tests, and Parkway Clinical Laboratories, a clinical diagnostic lab providing comprehensive routine and esoteric testing. He also held various senior-level positions within Genomics Collaborative, Inc. (a SeraCare Life Sciences Company), a full-scale clinical and genomics research company. Dr. Krenitsky received a B.S. in business management from the University of Scranton and an M.D. from Jefferson Medical College (now the Sidney Kimmel Medical College) in Philadelphia. He is a former member of the Board of Directors of the New York State Clinical Lab Association and of BioServe Biotechnologies, and serves on the Board of Directors of Lumicell."

Research Interest

His research interests include fields likeDiagnostics andMetabolomics